This article is a narrative review of the rapidly moving coronavirus disease 2019 vaccine field with an emphasis on clinical efficacy established in both randomized trials and postmarketing surveillance of clinically available vaccines. We review the major clinical trials that supported authorization for general use of the Janssen (Ad.26.CoV2), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines and the publicly available postmarketing information with the goal of providing a broad, clinically relevant comparison of efficacy and safety. This review is primarily focused on the US market.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, mRNA vaccine, Janssen (Ad.26.CoV2), vaccine efficacy trials, post-marketing vaccine surveillance,
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, mRNA vaccine, Janssen (Ad.26.CoV2), vaccine efficacy trials, post-marketing vaccine surveillance,